WebMay 20, 2024 · The first-in-human, multi-center, dose-escalation Phase 1 clinical trial of FT538 is designed to determine the maximum tolerated dose (MTD) of three once-weekly doses of FT538 in up to 105 adult ... WebMay 20, 2024 · Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the ...
FDA clears Fate Therapeutics
WebFT538: An Off-The-Shelf Natural Killer Cell Therapy for Acute Myeloid Leukaemia and Multiple Myeloma. FT538 is a universal, off-the-shelf natural killer (NK) cell cancer immunotherapy that is being developed by Californian biopharmaceutical company Fate Therapeutics.. The novel therapy is being tested in two separate treatment regimens in … WebNov 9, 2024 · FT538 is designed to enhance innate immunity in cancer patients, where endogenous NK cells are typically diminished in both number and function due to prior treatment regimens and tumor ... thomas tuchel new girl
Fate Therapeutics Announces FDA Clearance of IND Application for FT538 …
WebSep 15, 2024 · The FDA had cleared an Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy, in May. Now Read: Fate faces slew of analyst downgrades after J&J's ... WebMay 20, 2024 · The FDA has cleared Fate Therapeutics' (NASDAQ: FATE) Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. The Company plans to initiate ... WebNov 5, 2024 · There are multiple advantages in expanding treatment options beyond autologous primary T and NK cells, including the use of induced pluripotent stem cells (iPSC) to derive effector cells that can be uniformly manufactured at scale from renewable starting cellular material and where precision genetic engineering can be achieved at the … thomas tuchel newcastle